Literature DB >> 33456706

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.

Erika J Crosby, H Kim Lyerly, Zachary C Hartman.   

Abstract

Entities:  

Keywords:  T cell exhaustion; breast cancer; immune responses to cancer; tumor antigens/neoantigens; tumor immunology animal models

Year:  2021        PMID： 33456706      PMCID： PMC7800770          DOI： 10.18632/oncotarget.27861

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  18 in total

1.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Authors:  Peter Savas; Balaji Virassamy; Chengzhong Ye; Agus Salim; Christopher P Mintoff; Franco Caramia; Roberto Salgado; David J Byrne; Zhi L Teo; Sathana Dushyanthen; Ann Byrne; Lironne Wein; Stephen J Luen; Catherine Poliness; Sophie S Nightingale; Anita S Skandarajah; David E Gyorki; Chantel M Thornton; Paul A Beavis; Stephen B Fox; Phillip K Darcy; Terence P Speed; Laura K Mackay; Paul J Neeson; Sherene Loi
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

2.  Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.

Authors:  M V Dieci; A Prat; E Tagliafico; L Paré; G Ficarra; G Bisagni; F Piacentini; D G Generali; P Conte; V Guarneri
Journal:  Ann Oncol       Date:  2016-08-02       Impact factor: 32.976

3.  Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Authors:  Erika J Crosby; William Gwin; H Kim Lyerly; Zachary C Hartman; Kimberly Blackwell; Paul K Marcom; Serena Chang; Holden T Maecker; Gloria Broadwater; Terry Hyslop; Sungjin Kim; Andre Rogatko; Veronica Lubkov; Joshua C Snyder; Takuya Osada; Amy C Hobeika; Michael A Morse
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

Review 4.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 5.  T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.

Authors:  Lin Yu; Jianhua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-23       Impact factor: 4.553

6.  Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.

Authors:  Keith L Knutson; Matthew S Block; Nadine Norton; Courtney L Erskine; Timothy J Hobday; Allan B Dietz; Douglas Padley; Michael P Gustafson; Danell Puglisi-Knutson; Toni Kay Mangskau; Saranya Chumsri; Amylou C Dueck; Lavakumar Karyampudi; Glynn Wilson; Amy C Degnim
Journal:  Clin Cancer Res       Date:  2019-11-22       Impact factor: 12.531

7.  CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.

Authors:  Li-Chung Tsao; Erika J Crosby; Timothy N Trotter; Pankaj Agarwal; Bin-Jin Hwang; Chaitanya Acharya; Casey W Shuptrine; Tao Wang; Junping Wei; Xiao Yang; Gangjun Lei; Cong-Xiao Liu; Christopher A Rabiola; Lewis A Chodosh; William J Muller; Herbert Kim Lyerly; Zachary C Hartman
Journal:  JCI Insight       Date:  2019-12-19

8.  Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.

Authors:  Erika J Crosby; Chaitanya R Acharya; Anthony-Fayez Haddad; Christopher A Rabiola; Gangjun Lei; Jun-Ping Wei; Xiao-Yi Yang; Tao Wang; Cong-Xiao Liu; Kay U Wagner; William J Muller; Lewis A Chodosh; Gloria Broadwater; Terry Hyslop; Jonathan H Shepherd; Daniel P Hollern; Xiaping He; Charles M Perou; Shengjie Chai; Benjamin K Ashby; Benjamin G Vincent; Joshua C Snyder; Jeremy Force; Michael A Morse; Herbert K Lyerly; Zachary C Hartman
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 13.801

9.  A decade of immune-checkpoint inhibitors in cancer therapy.

Authors:  Caroline Robert
Journal:  Nat Commun       Date:  2020-07-30       Impact factor: 14.919

10.  HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression.

Authors:  Alan Chen Chen; Renhuan Xu; Tao Wang; Junping Wei; Xiao-Yi Yang; Cong-Xiao Liu; Gangjun Lei; Herbert Kim Lyerly; Teri Heiland; Zachary Conrad Hartman
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751
View more
  1 in total

Review 1.  Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.

Authors:  Alexander Batista-Duharte; Fakhri Hassouneh; Pablo Alvarez-Heredia; Alejandra Pera; Rafael Solana
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.